Bausch Health to pay $45M for misleading disclosures

Bausch Health

The Securities and Exchange Commission charged Bausch Health (formerly Valeant Pharmaceuticals) and three former executives for improper revenue recognition and misleading disclosures in SEC filings and earnings presentations.

This is Members-only content
To continue reading, choose one of the options below: